CANSINO BIOLOGICS INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 18.82 HKD | +2.51% |
|
+14.06% | -20.08% |
| Apr. 22 | Cansino Bio Gets Nod for China Clinical Trials of Haemophilus Influenzae Vaccine | MT |
| Apr. 22 | Cansino Biologics Pneumococcal Vaccine's Phase I Trial Offers Positive Results | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 11,730 | 62,629 | 53,868 | 24,455 | 11,353 | 7,950 | - | - |
| Enterprise Value (EV) 1 | 11,142 | 58,324 | 49,253 | 24,455 | 11,353 | 7,734 | 7,080 | 7,017 |
| P/E ratio | -74.8 x | -86.4 x | 19 x | -16 x | -3.65 x | -12.3 x | -120 x | 12.7 x |
| Yield | - | - | 0.54% | - | - | - | - | - |
| Capitalization / Revenue | - | 3,377 x | 12.5 x | 23.6 x | 31.8 x | 9.27 x | 6.05 x | 4.06 x |
| EV / Revenue | - | 3,145 x | 11.5 x | 23.6 x | 31.8 x | 9.02 x | 5.39 x | 3.58 x |
| EV / EBITDA | -62.8 x | -158 x | 24.4 x | -24.6 x | -7.01 x | -48.6 x | 53.4 x | 8.37 x |
| EV / FCF | -39.8 x | -78.9 x | 58.2 x | -8.36 x | -7.48 x | -12.9 x | -23.1 x | 17.7 x |
| FCF Yield | -2.52% | -1.27% | 1.72% | -12% | -13.4% | -7.74% | -4.34% | 5.66% |
| Price to Book | 7.28 x | 6.06 x | 4.54 x | 1.97 x | 1 x | 0.88 x | 0.86 x | 0.82 x |
| Nbr of stocks (in thousands) | 222,650 | 247,450 | 247,450 | 246,766 | 246,766 | 247,044 | - | - |
| Reference price 2 | 52.68 | 148.6 | 146.8 | 58.95 | 21.40 | 17.42 | 17.42 | 17.42 |
| Announcement Date | 3/27/20 | 2/25/21 | 2/25/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | 18.54 | 4,300 | 1,035 | 357.1 | 857.5 | 1,313 | 1,959 |
| EBITDA 1 | -177.5 | -369.1 | 2,021 | -993.4 | -1,621 | -159 | 132.6 | 838.2 |
| EBIT 1 | -200 | -400.9 | 1,941 | -1,181 | -1,936 | -393 | -68.65 | 641.8 |
| Operating Margin | - | -2,161.66% | 45.14% | -114.12% | -542.3% | -45.83% | -5.23% | 32.77% |
| Earnings before Tax (EBT) 1 | -156.8 | -396.6 | 1,937 | -1,184 | -1,932 | -654 | -445 | -320 |
| Net income 1 | -156.8 | -396.6 | 1,914 | -909.4 | -1,447 | -610.5 | -408.5 | -320 |
| Net margin | - | -2,138.9% | 44.52% | -87.9% | -405.31% | -71.19% | -31.1% | -16.34% |
| EPS 2 | -0.7041 | -1.720 | 7.740 | -3.680 | -5.870 | -1.422 | -0.1456 | 1.372 |
| Free Cash Flow 1 | -280.2 | -739.3 | 846.9 | -2,927 | -1,518 | -599 | -307 | 397 |
| FCF margin | - | -3,986.61% | 19.7% | -282.87% | -425.22% | -69.85% | -23.37% | 20.27% |
| FCF Conversion (EBITDA) | - | - | 41.9% | - | - | - | - | 47.36% |
| FCF Conversion (Net income) | - | - | 44.24% | - | - | - | - | - |
| Dividend per Share 2 | - | - | 0.8000 | - | - | - | - | - |
| Announcement Date | 3/27/20 | 2/25/21 | 2/25/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 1,024 | 1,214 | - | 130.4 | 77.6 | - | - | - | - | 181.5 | 225.6 | 225.6 | 225.6 | 229.6 | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT | 458.6 | 645.5 | - | - | - | -507.7 | - | - | - | - | - | - | - | - | - |
| Operating Margin | 44.77% | 53.18% | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net income | - | - | - | - | - | - | -139.5 | -701.9 | -143.6 | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | 1.600 | 2.350 | 0.4900 | - | - | -1.760 | -0.5700 | -2.840 | -0.5800 | - | -0.3259 | -0.3259 | -0.3259 | -0.3098 | - |
| Dividend per Share 2 | - | 0.8000 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 10/28/21 | 2/25/22 | 4/28/22 | 9/8/22 | 10/28/22 | 2/27/23 | 4/28/23 | 8/30/23 | 10/30/23 | 2/23/24 | - | - | - | - | - |
1CNY in Million2CNY
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | - |
| Net Cash position 1 | 588 | 4,304 | 4,614 | - | - | 216 | 870 | 933 |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow 1 | -280 | -739 | 847 | -2,927 | -1,518 | -599 | -307 | 397 |
| ROE (net income / shareholders' equity) | -15.9% | -10.5% | 27.1% | -12.4% | -24.1% | -6.93% | -1.23% | 6.63% |
| ROA (Net income/ Total Assets) | -12.2% | -9.3% | 25.9% | - | -13.9% | -7.6% | -5.6% | -4.3% |
| Assets 1 | 1,290 | 4,266 | 7,383 | - | 10,394 | 8,033 | 7,295 | 7,442 |
| Book Value Per Share 2 | 7.230 | 24.50 | 32.30 | 30.00 | 21.40 | 19.70 | 20.30 | 21.20 |
| Cash Flow per Share 2 | -0.8400 | -2.030 | 8.290 | -7.640 | -3.680 | -0.6900 | 0.3500 | 1.840 |
| Capex 1 | 110 | 270 | 1,203 | 1,075 | 610 | 192 | 228 | 255 |
| Capex / Sales | - | 1,455.39% | 27.98% | 103.91% | 170.87% | 22.4% | 17.34% | 13.03% |
| Announcement Date | 3/27/20 | 2/25/21 | 2/25/22 | 2/27/23 | 2/23/24 | - | - | - |
1CNY in Million2CNY
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
17.42
CNY
Average target price
24.32
CNY
Spread / Average Target
+39.63%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -20.08% | 1.1B | |
| -4.66% | 86.13B | |
| +1.32% | 39.82B | |
| -19.27% | 30.42B | |
| +57.86% | 25.23B | |
| -17.69% | 11.6B | |
| -43.00% | 11.51B | |
| -9.14% | 11.95B | |
| +5.24% | 8.71B | |
| -8.42% | 8.12B |
- Stock Market
- Equities
- 6185 Stock
- Financials CanSino Biologics Inc.
